-
02:44:04 PM

MRK Stock News

09/28/23 6:45 AM
NYSE : MRK
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
Merck, known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration has accepted for priority review a new Biologics License Application for sotatercept, Merck’ s novel investigational activin signaling inhibitor, for the treatment of adult patients with pulmonary arterial hypertension.
RHEA-AI
neutral
09/22/23 6:45 AM
NYSE : MRK
clinical trial
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Merck, known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’ s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain types of metastatic...
RHEA-AI
negative
09/22/23 6:00 AM
NYSE : MRK
clinical trial
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Merck, known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen and Astellas, evaluating KEYTRUDA, Merck’ s anti-PD-1 therapy, in combination with Padcev versus chemotherapy in patients with previously untreated locally advanced or...
RHEA-AI
negative
09/20/23 6:45 AM
NYSE : MRK
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Merck, known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration has accepted for priority review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’ s anti-PD-1 therapy, in combination with external beam radiotherapy plus concurrent chemotherapy, followed by...
RHEA-AI
negative
09/19/23 6:45 AM
NYSE : MRK
clinical trial
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Merck, known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration has accepted and granted priority review for a supplemental new drug application seeking approval for WELIREG, Merck’ s oral hypoxia-inducible factor-2 alpha inhibitor, for the treatment of adult patients with advanced renal cell carcinoma...
RHEA-AI
neutral
09/15/23 9:10 AM
NYSE : MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Merck, known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’ s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of KEYTRUDA, Merck’ s anti-PD-1 therapy, for the adjuvant treatment of adults with non-small cell lung cancer, who are at high risk of recurrence...
RHEA-AI
negative
09/11/23 7:45 AM
NYSE : MRK
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
Merck, known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’ s novel investigational activin signaling inhibitor biologic, for adults with pulmonary arterial hypertension at the European Respiratory Society International Congress 2023. A new exploratory post-hoc analysis of right heart...
RHEA-AI
neutral
09/07/23 6:45 AM
NYSE : MRK
European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
Merck, known as MSD outside of the United States and Canada, announced today that the European Commission has approved an expanded indication for ERVEBO for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease caused by Zaire ebolavirus. The European Commission’ s expanded approval of ERVEBO for children 1 year of...
RHEA-AI
neutral
09/05/23 8:00 AM
NYSE : MRK
Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics
Merck, known as MSD outside of the United States and Canada, announced new, 10- year long-term follow-up data published in the peer reviewed journal, Pediatrics, for girls and boys who received a three-dose regimen of GARDASIL ® 9 at 9-15 years old. The LTFU study was conducted from 2009 through 2021 across 13 countries and five continents. In the U.S., GARDASIL 9 is...
RHEA-AI
neutral